New treatment for mantle cell lymphoma after BTK inhibitor failure
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination treatment for people with mantle cell lymphoma that has come back or not responded to a BTK inhibitor. It aims to see if this new approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have mantle cell lymphoma that came back or did not respond to a BTK inhibitor (a type of targeted drug).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, and kidney function are within safe limits.
- If you could become pregnant, you agree to use effective birth control and have a negative pregnancy test before starting.
- You are not pregnant or breastfeeding and do not have other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs for people with mantle cell lymphoma that has not responded to or has returned after treatment with a BTK inhibitor. The drugs aim to block cancer cell growth and survival pathways to potentially control the disease.
This trial tests a new oral drug, TT-01488, taken with a standard antibody treatment (rituximab) for mantle cell lymphoma. It may help people who have either not been treated yet or whose cancer has returned, and aims to improve outcomes with fewer side effects.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
This trial is testing a combination of three drugs (polatuzumab vedotin, bendamustine, and rituximab) for people with mantle cell lymphoma that has progressed after a BTK inhibitor. The goal is to see if this combination can help control the lymphoma. You'll receive the treatment intravenously (by IV) over several cycles.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.